Summit Therapeutics (SMMT)

Summit Therapeutics (SMMT) stock research: performance, analysts' price targets, earnings, revenue and margins, technicals and insider trades.

Summit Bounces After FDA Setback and New Trial

Summit Therapeutics rose 3.2% today even as the S&P 500 and Nasdaq 100 each fell 1.2%. Traders are weighing the FDA’s rejection of its lung-cancer drug application against a newly launched global trial, after steep recent losses.

Published 2026-11-19 18:00:42 UTC.